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H. pylori-associated gastric
lymphoma: Complete remission
The  patient  was  afebrile  with  normal  ﬁndings  on  physical
examination.  Laboratory  tests  reported  the  patient  to  be
HIV-positive  with  a  viral  load  of  1,240,000  copies/mL,  a  total
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Linfoma gástrico asociado a H. pylori:
remisión completa con tratamiento de TARAA
y erradicación de H. pylori en un paciente
VIH-positivo
B-cell  non-Hodgkin’s  lymphoma  (NHL)  is  one  of  the  most  fre-
quently  observed  neoplasias  in  patients  with  HIV  infection.
This  association  has  been  observed  since  the  beginning  of  the
HIV  epidemic  and  is  considered  an  AIDS-deﬁning  condition.1
NHL  presents  in  extranodal  form  more  frequently  in
HIV-positive  than  in  HIV-negative  patients.  The  most  com-
monly  affected  extranodal  site  is  the  gastrointestinal  tract.2
According  to  histologic  subtype,  diffuse  large  B-cell  lym-
phoma  (DLBCL)  and  Burkitt’s  lymphoma  are  the  most
common  forms  of  NHL.  It  is  estimated  that  the  incidence
of  NHL  in  patients  with  HIV  infection  is  100  times  greater
than  in  the  general  population.3
On  the  other  hand,  gastric  MALT  lymphomas  are  often
associated  with  Helicobacter  pylori  (H.  pylori) infection.
Gastric  MALT  lymphoma  is  etiopathologically  related  to
chronic  H.  pylori  infection.  Complete  remission  after
H.  pylori  eradication  has  been  described  in  low-grade  MALT
lymphomas  as  well  as  in  high-grade  MALT  lymphomas  in  both
immune-competent  and  AIDS  patients,  without  the  use  of
anti-cancer  chemotherapeutic  agents.4 Only  a  few  reports
have  described  the  complete  remission  of  H.  pylori-positive
DLBCL  in  an  HIV+  patient  treated  with  HAART  and  H.  pylori
eradication,  alone.5
We  present  herein  an  HIV+  patient  with  H.  pylori-positive
DLBCL.
A  47-year-old  man  presented  with  a  3-month  history
of  heartburn,  epigastric  pain,  and  weight  loss  of  5  kg.
 Please cite this article as: Verduzco-Rodríguez L, Ramírez-Pérez
F, Clendenin RM, Cruz Lara LA. Linfoma gástrico asociado a H. pylori:
remisión completa con tratamiento de TARAA y erradicación de H.
pylori en un paciente VIH-positivo. Revista de Gastroenterología de
México. 2016. http://dx.doi.org/10.1016/j.rgmx.2015.12.004
(
s
w
2255-534X/© 2016 Asociacio´n Mexicana de Gastroenterolog´ıa. Published
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nymphocyte  count  of  2,137/mm3, and  CD4  of  725/mm3.
Upper  gastrointestinal  endoscopy  revealed  an  8  cm  ulcer-
ted  gastric  tumor  on  the  greater  curvature.  Multiple
iopsies  were  taken  for  pathologic  and  immunohistochem-
cal  analysis.  Analysis  conﬁrmed  a  hypercellular  neoplastic
esion  of  lymphoid  origin  that  almost  entirely  replaced  the
ucosa  with  apoptotic  cells  and  isolated  polymorphonu-
lear  cells.  Giemsa  staining  revealed  bacilli  morphologically
ompatible  with  H.  pylori  (ﬁg.  1).  Immunohistochemical
esults  were  CD3−, CD5−, CD10−, CD20+,  CD45+,  BCL6+,
appa  +,  and  Lambda-  (ﬁg.  2).
The  diagnoses  reached  were  diffuse  large  B-cell  gastric
ymphoma,  HIV  infection,  and  H.  pylori-associated  gastritis.
An  abdominal  CT  scan  showed  a  gastric  mass  without
pparent  adenomegaly  or  metastasis.
The  patient  was  prescribed  highly  active  antiretroviral
herapy  (HAART)  (Efavirenz  600  mg/  Emtricitabine  200  mg/
enofovir  300  mg  q.d.)  and  H.  pylori  eradication  ther-
py  (Omeprazole  20  mg/Clarithromycin  500  mg  Amoxicillin
000  mg  q.12  h  10  days).  No  antineoplastic  chemotherapy
as  given.
At  one-year  follow  up,  the  patient  is  asymptomatic  with
o  evidence  of  tumor  activity  on  endoscopy  or  biopsy,  with
n  undetectable  viral  load,  and  a  CD4  count  of  543/mm3.
One  year  after  the  initiation  of  treatment  with  HAART
nd  H.  pylori  eradication  and  no  use  of  anticancer  agents,
he  patient  remains  in  complete  remission.  Ribiero  et  al.
eport  a  similar  case  in  which  a  patient  achieved  complete
emission  without  the  use  of  antineoplastic  agents  (in  MALT
ymphoma)4 and  Okame  et  al.  reported  a  case  of  stage  IE
IDS-related  gastric  DLBCL  that  responded  to  H.  pylori  erad-
cation  therapy  and  HAART.5
HIV  patients  with  gastric  NHL  treated  only  with  HAART
nd  H.  pylori  eradication  therapy  have  a  relatively  good
rognosis.  A  French  study  described  8  patients  with  MALT
ymphoma,  6  of  which  had  gastric  involvement.  Of  these,
 had  concurrent  H.  pylori  infection.  Through  the  use  of
AART  and  H.  pylori  eradication,  complete  remission  was
chieved  in  100%  of  the  patients  with  H.  pylori-associated
astric  lymphoma.6 In  another  study,  11  out  of  16  patients
68.8%)  with  pure  (de  novo)  DLBCL  achieved  complete  remis-
ion  after  H.  pylori  eradication  therapy.7
There  are  complete  remission  rates  of  approximately  80%
ith  antibiotic  therapy.  This  is  mainly  due  to  the  fact  that
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Figure  1  Giemsa  stain.  A  and  B)  Bacilli  morphologically  compatible  with  H.  pylori.
Figure  2  Immunohistochemical  analysis.  A)  Positive  immunoreaction  to  CD45  in  neoplastic  lymphocytes  and  in  reactive  B  and  T
lymphocytes.  B)  Positive  immunoreaction  to  CD20  in  neoplastic  lymphocytes.  C)  Focally  positive  Bcl-6  immunoreaction  in  neoplastic
cells. D)  Focally  positive  immunoreaction  for  Kappa  in  neoplastic  cells.
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lymphoma  growth  in  the  initial  stages  of  lymphomagene-
sis  is  stimulated  by  contact  between  neoplastic  B  cells  and
intratumoral  H.  pylori-speciﬁc  T  cells.  It  then  follows  that
H.  pylori  eradication  treatment  eliminates  this  stimulus.8 In
addition,  certain  protein  expression  is  related  to  good  prog-
nosis.  CD-10  and  BCL-6  are  regarded  as  important  markers
in  diagnosing  germinal  center  B  cell  DLBCL  and  many  stud-
ies  have  suggested  that  CD10  and  BCL-6  expression  in  DLBCL
predicts  better  overall  survival  rates.9
The  treatment  of  DLBCL  has  evolved  from  routine
gastrectomy  to  more  conservative  therapies  such  as  radio-
therapy  in  little  more  than  a  decade.  The  outcome  of  our
case  supports  the  suggestion  in  recent  trials  that  excellent
results  can  be  obtained  by  treating  limited-stage  H.  pylori-
positive  gastric  DLBCL  with  antibiotics  alone,  reserving
chemo-radiotherapy  as  an  option  for  unresponsive  patients
and  those  with  poor-prognosis.10
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